Description

Atracurium Besylate is a non-depolarizing neuromuscular blocking agent belonging to the benzylisoquinolinium class. It is a critical pharmaceutical intermediate and active pharmaceutical ingredient (API) used in the formulation of injectable anesthetic agents. This compound is essential for manufacturers in the pharmaceutical and biotechnology sectors requiring reliable, high-purity raw materials for sterile injectable production. Its primary value lies in providing controlled muscle relaxation during surgical procedures and intensive care.

Application

• Primary use as an Active Pharmaceutical Ingredient (API) in the manufacture of injectable neuromuscular blocking agents.
• Critical intermediate in pharmaceutical synthesis for producing finished dosage forms.
• Used in research and development of new anesthetic and neuromuscular blocking drugs.
• Essential for compounding hospital and clinical pharmacy preparations under strict aseptic conditions.
• Reference standard in analytical laboratories for quality control and method development.
• Starting material for the production of generic pharmaceutical formulations.

Basic Information

Product Name	Atracurium Besylate
CAS No.	64228-79-1
Molecular Formula	C65H82N2O18S2
Molecular Weight	1243.5 g/mol
Synonyms	Atracurium Besilate; 2,2'-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium dibenzenesulfonate; 33A74; BW 33A; Nimbex (as besylate salt); cis-Atracurium Besylate precursor; Laudexium methylsulfate analogue; Benzenesulfonic acid, compd. with 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] (2:1)
EINECS	Contact for details

Quality Control

Our Atracurium Besylate is produced and tested under strict quality management systems. It undergoes rigorous analytical testing to ensure identity, purity, and consistency, meeting high standards for pharmaceutical use. Certificates of Analysis (COA) are provided with each batch, detailing results for assay, related substances, residual solvents, and other critical parameters. We support compliance with cGMP, ICH Q7, and other relevant pharmaceutical guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment to prevent degradation. For long-term storage, consider desiccated conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 5.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤ 20 ppm
Specific Rotation	Contact for details
pH (in solution)	3.0 - 5.0

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.